Shares of United Therapeutics Corp. (NASDAQ:UTHR) gapped up prior to trading on Monday . The stock had previously closed at $126.57, but opened at $126.92. United Therapeutics Corp. shares last traded at $127.67, with a volume of 238,264 shares traded.

Several analysts have issued reports on UTHR shares. Wedbush reissued an “outperform” rating and issued a $229.00 price objective on shares of United Therapeutics Corp. in a research note on Thursday, July 28th. HC Wainwright reaffirmed a “hold” rating on shares of United Therapeutics Corp. in a research note on Friday, July 29th. Zacks Investment Research raised shares of United Therapeutics Corp. from a “hold” rating to a “strong-buy” rating and set a $125.00 price target for the company in a research note on Tuesday, July 5th. Argus downgraded shares of United Therapeutics Corp. from a “buy” rating to a “hold” rating and set a $114.00 price target for the company. in a research note on Tuesday, May 24th. Finally, Ladenburg Thalmann downgraded shares of United Therapeutics Corp. from a “buy” rating to a “neutral” rating in a research note on Friday, April 29th. Nine analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $135.64.

The company has a 50-day moving average price of $118.34 and a 200 day moving average price of $116.31. The firm has a market capitalization of $5.63 billion and a P/E ratio of 6.26.

United Therapeutics Corp. (NASDAQ:UTHR) last posted its quarterly earnings results on Thursday, July 28th. The biotechnology company reported $4.55 earnings per share for the quarter, beating the consensus estimate of $3.22 by $1.33. During the same period last year, the company earned $2.55 EPS. The firm earned $412.60 million during the quarter, compared to analysts’ expectations of $395.15 million. The business’s quarterly revenue was up 18.8% on a year-over-year basis. On average, analysts forecast that United Therapeutics Corp. will post $15.82 EPS for the current fiscal year.

In other news, CEO Martine A. Rothblatt sold 1,249 shares of the stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $125.78, for a total value of $157,099.22. Following the completion of the sale, the chief executive officer now owns 1,389 shares of the company’s stock, valued at approximately $174,708.42. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Tommy G. Thompson sold 2,000 shares of the stock in a transaction that occurred on Wednesday, June 8th. The shares were sold at an average price of $115.62, for a total transaction of $231,240.00. Following the completion of the sale, the director now directly owns 2,000 shares of the company’s stock, valued at approximately $231,240. The disclosure for this sale can be found here.

Several institutional investors recently bought and sold shares of the company. Schwab Charles Investment Management Inc. boosted its position in United Therapeutics Corp. by 17.5% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 119,309 shares of the biotechnology company’s stock worth $18,685,000 after buying an additional 17,732 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in United Therapeutics Corp. by 256.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 37,800 shares of the biotechnology company’s stock worth $5,920,000 after buying an additional 27,200 shares during the last quarter. State of Tennessee Treasury Department boosted its position in United Therapeutics Corp. by 29.9% in the fourth quarter. State of Tennessee Treasury Department now owns 86,900 shares of the biotechnology company’s stock worth $13,609,000 after buying an additional 20,000 shares during the last quarter. Matarin Capital Management LLC bought a new position in United Therapeutics Corp. during the fourth quarter worth $4,154,000. Finally, Eaton Vance Management boosted its position in United Therapeutics Corp. by 11.5% in the fourth quarter. Eaton Vance Management now owns 8,360 shares of the biotechnology company’s stock worth $1,309,000 after buying an additional 860 shares during the last quarter.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.